Medical Device News Update - August 2024
FDA approvals, warning letters and Class I recalls issued during August 2024
Monthly roundup of FDA approvals, warning letters and recalls issued in August 2024
Each month, Let’s Talk Risk! (LTR) provides a comprehensive summary of new device approvals or clearances, warning letters, and Class I recall announcements issued by the FDA in the previous month.
As a risk practitioner, it is very important to stay up to date with the latest regulatory developments affecting the medical device industry. A review of latest innovations approved or cleared by the FDA helps in understanding different ways the agency evaluates benefit-risk of medical devices when reviewing their safety and effectiveness. Warning letters and recall announcements are useful in building awareness of gaps in quality management system and the risk management process that should be addressed before they are cited by the FDA.
Only publicly available information is curated in this article. Links to relevant sources are provided in the footnotes.
Quick Summary
New device approvals/clearances
A high throughput genetic sequencing based tumor profiling test (De Novo DEN230046).
A device to reduce bacterial load on respiratory devices and accessories (De Novo DEN210037).
A home-based test for qualitative detection of syphilis (De Novo DEN230090).
A rapid UV disinfection chamber for ultrasound probes (De Novo DEN230067).
An implantable nerve stimulation device to reduce post-amputation pain, breakthrough device designation (PMA, Original, P230020).
A stent system for treatment of pulmonary artery stenosis, breakthrough device designation (PMA, Original, P240003).
A companion diagnostic assay for qualitative detection of 517 genetic variants in tumor tissues from patients considered for VITRAKVI® and RETEVMO® therapies (PMA, Original, P230011).
A companion diagnostic assay for detection of MAGE-A4 protein as an aid in identifying patients considered for TECELRA® immunotherapy (PMA, Original, P230016).
A total of 283 devices were cleared through the 510(k) pathway during August 2024. Days to FDA decision ranged from 1 to 1062 days with a median of 116 days. Top 5 medical specialties were Orthopedic (OR), Radiology (RA), General & Plastic Surgery (SU), Cardiovascular (CV), and Dental (DE) accounting for 62% (176/283) of devices cleared.
FDA warning letters
Shenzhen Moyeah Intelligent Life Technology Co.: Marketing of various CPAP cleaning products and accessories without FDA authorization.
Adventure Innovations LLC: Marketing of UV based cleaning/disinfecting devices for CPAP and accessories without FDA authorization.
Natures Pillows, Inc. and Top Dog Direct, LLC: Marketing of sanitizers for CPAP and accessories without FDA authorization.
LEEL Tech: Marketing of sanitizers for CPAP and accessories without FDA authorization.
Class I recall announcements
Smiths Medical: multiple issues with older versions of the software in the CADD-Solis and CADD-Solis VIP Ambulatory infusion pumps.
Medtronic: correction for NIM Vital Nerve Monitoring System due to the potential for false negative response.
Abiomed: removal of 9 Impella CP with SmartAssist Systems due to release of products that failed QC inspection.
ICU Medical: diminished battery life due to manufacturing error which can impact infusion pump operation.
Defibtech, LLC: motor failure in a chest compression device.
Medline Industries, LP: defective syringes in convenience kits that may break or leak.
Inari Medical: patient injuries and deaths due to entrapment of a clot removing catheter.
Let us take a closer look.
Keep reading with a 7-day free trial
Subscribe to Let's Talk Risk! to keep reading this post and get 7 days of free access to the full post archives.